This database contains 1041 studies, archived under the term: "male"
Click here to filter this large number of results.
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease
Salloway, Stephen,
Mintzer, Jacobo,
Cummings, Jeffrey L.,
Geldmacher, David,
Sun, Yijun,
Yardley, Jane,
Mackell, Joan
To better understand responses in the large number of US-based patients included in a global trial of donepezil 23 mg/d versus 10 mg/d for moderate-to-severe Alzheimer’s disease (AD), post hoc exploratory analyses were performed to assess the efficacy and safety in US and non-US (rest of the world [RoW]) patient subgroups. In both subgroups, donepezil […]
Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients
Han, Hyun Jeong,
Kim, Byeong C.,
Lee, Jun-Young,
Ryu, Seung-Ho,
Na, Hae-Ri,
Yoon, Soo Jin,
Park, Hyun Young,
Shin, Joon Hyun,
Cho, Soo-Jin,
Yi, Hyon Ah,
Choi, Mun Seong,
Heo, Jae-Hyeok,
Park, Kyung Won,
Kim, Kwang K.,
Choi, Seong Hye
Background/aims: The apolipoprotein E (APOE) genotype in response to pharmacological treatments in patients with Alzheimer’s disease (AD) remains a matter of controversy. This analysis investigated the effect of the APOE genotype on the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine patch in patients with mild to moderate AD.; Methods: Two hundred […]
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s disease: a subgroup analysis in patients already taking or not taking concomitant memantine
Doody, Rachelle S.,
Geldmacher, David S.,
Farlow, Martin R.,
Sun, Yijun,
Moline, Margaret,
Mackell, Joan
Background/aims: A large multicenter trial of donepezil 23 mg/day versus donepezil 10 mg/day for moderate-to-severe Alzheimer’s disease allowed patients taking concomitant memantine. We evaluated the efficacy/safety of donepezil 23 and 10 mg/day in this trial, with respect to concomitant memantine use.; Methods: Prespecified analysis of data from a 24-week, randomized, double-blind trial. Patients were randomized […]
Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study
Beauchet, Olivier,
Launay, Cyrille P.,
Allali, Gazan,
Watfa, Gilles,
Gallouj, Karim,
Herrmann, François R.,
Annweiler, Cedric
Background: Anti-dementia drugs may improve gait performance. No comparison between acetylcholinesterase inhibitors (CEIs) and memantine-related changes in gait variability has been reported. The objectives of this study were to 1) quantify and compare the mean values and coefficients of variation (CoV) of stride time in demented patients with Alzheimer’s disease and related disorders (ADRD) before […]
Psychosocial group intervention to enhance self-management skills of people with dementia and their caregivers: study protocol for a randomized controlled trial
Laakkonen, Marja-Liisa,
Hölttä, Eeva H.,
Savikko, Niina,
Strandberg, Timo E.,
Suominen, Merja,
Pitkälä, Kaisu H.
Background: After diagnosis of a dementing illness, patients and their spouses have many concerns related to the disease and their future. This often leads to poor psychological well-being and reduced health-related quality of life (HRQoL) of the family. Support for self-management skills has been proven to be an effective method to improve prognosis of asthma, […]
CORDIAL: cognitive rehabilitation and cognitive-behavioral treatment for early dementia in Alzheimer disease: a multicenter, randomized, controlled trial
Kurz, Alexander,
Thöne-Otto, Angelika,
Cramer, Barbara,
Egert, Silvia,
Frölich, Lutz,
Gertz, Hermann-Josef,
Kehl, Victoria,
Wagenpfeil, Stefan,
Werheid, Katja
Cognitive rehabilitation (CR) is a promising treatment approach for older adults with dementia because it aims at supporting the management of day-to-day problems. There is insufficient evidence regarding whether CR provides clinically meaningful benefits. In this study, we evaluated the feasibility, acceptance, efficacy, and usefulness of a CR intervention in a multicenter, randomized, controlled trial […]
Pain and distress in advanced dementia: choosing the right tools for the job
Objective: There is a concern that pain is under-recognized in dementia. However, there may be other causes of distress. We wished to evaluate the utility of a distress tool and a pain tool.; Methods: Nursing home residents with advanced dementia were observed using pain (Pain Assessment in Advanced Dementia scale (PAINAD)) and distress (Disability Distress […]
Passive movement therapy in severe paratonia: a multicenter randomized clinical trial
Background: Paratonia causes severe movement dysfunction in late stage dementia. Passive Movement Therapy (PMT) is often used to decrease high muscle tone, but the efficacy has never been shown. The objective of this study is to investigate the effect of PMT on muscle tone after two and four weeks of treatment.; Methods: This study comprised […]
Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg
Herrschaft, Horst,
Nacu, Anatol,
Likhachev, Sergey,
Sholomov, Ilya,
Hoerr, Robert,
Schlaefke, Sandra
A multi-centre, double-blind, randomised, placebo-controlled, 24-week trial with 410 outpatients was conducted to demonstrate efficacy and safety of a 240 mg once-daily formulation of Ginkgo biloba extract EGb 761(®) in patients with mild to moderate dementia (Alzheimer’s disease or vascular dementia) associated with neuropsychiatric symptoms. Patients scored 9 to 23 on the SKT cognitive battery, […]